Kim P. Kamdar

This profile gathers the share dealings of Kim P. Kamdar across 5 companies, led by Singular Genomics Systems, Inc., Sera Prognostics, Inc. and Evofem Biosciences, Inc. We count 23 filings; the first trade dates from 19 March 2014 and the latest from 10 July 2026.

On the open market, the record shows 5 purchases worth €337k and 5 sales worth €334k. The net balance comes to €3,011 on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 5 share grants.

Half of the purchases are above €45k and half below. Of 4 purchases, 4 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 14 July 2026, reports a share grant in Sera Prognostics, Inc. The last purchase on record was published on 21 June 2021, which is 1,952 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.